Details of the Drug
General Information of Drug (ID: DMRPFCS)
Drug Name |
TEFLUDAZINE
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Tefludazine; Tefludazine [INN]; Tefludazinum [Latin]; Tefludazina [Spanish]; Lu 18-012; CHEMBL95636; trans-4-[3-(p-fluorophenyl)-6-(trifluoromethyl)-1-indanyl]-1-piperazineethanol; 2-(4-(trans-3-(4-Fluorphenyl-6-trifluormethyl-1-indanyl)-1-piperazinyl)ethanol; 80273-79-6; Tefludazinum; Tefludazina; trans-4-(3-(p-Fluorophenyl)-6-(trifluoromethyl)-1-indanyl)-1-piperazineethanol; 1-Piperazineethanol, 4-(3-(4-fluorophenyl)-2,3-dihydro-6-(trifluoromethyl)-1H-indel-1-yl)-, trans-(+-)-; (1R,3S)-Tefludazine; AC1L2FT8; AC1Q4JR0
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 408.4 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.7 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 7 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||